ClinicalTrials.gg
CompletedNCT04128540Updated Jul 8, 2022

Erector Spinae Plane Block Versus Fentanyl Infusion in Pediatric Patients Undergoing Aortic Coarcitectomy

A Phase 3 interventional study of Fentanyl and Erector spinae plane block in Aortic Coarctation, Erector Spinae Plane Block and Paediatric, sponsored by Cairo University. Completed at 1 site in Egypt. Open to participants aged 3 Months to 12 Months. Per ClinicalTrials.gov, last updated 2022-07-08.

Sponsored by Cairo University · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
3 Months to 12 Months
Sex
All
01

Study summary

Pain is considered to be subjective, however in children it is believed to be felt rather than expressed, because they often depend on the caregiver for their safety and well-being.

There is significant pain after thoracotomy surgery because of pleural and muscular damage, ribcage disruption, and intercostal nerve damage during surgery, which if not effectively managed, it will lead to various systemic complications; pulmonary (atelectasis, pneumonia, and stasis of bronchial secretions), cardiovascular (increased oxygen consumption and tachycardia), musculoskeletal (muscle weakness), increased neuro-hormonal response and prolonged hospital stay. So adequate and sufficient post-operative analgesia for paediatric patients is mandatory.

The use of highly potent opioids for paediatric cardiac anaesthesia has gained widespread popularity during the last 20 years.In addition to the important advantage of hemodynamic stability, the large-dose opioid-based anaesthetic techniques also blunt the stress response, However, large doses can cause oversedation, respiratory depression, and prolonged mechanical ventilation after surgery.

Erector Spinae Plane Block (ESPB), recently developed by Forero et al, is a novel technique in management of thoracic neuropathic pain guided by ultrasound. It became popular because it is much safer and easily administered than other alternative regional techniques as thoracic paravertebral and thoracic epidural block.

To our knowledge, Erector Spinae Plane Block (ESPB) performed in aortic coarcitectomy operations has not been investigated yet.This has encouraged the performance of the present study.

Read the detailed description

Our study will be designed to estimate and compare the analgesic effect of single shot erector spinae plane block in pediatric patients undergoing aortic coarcitectomy via thoracotomy incision versus fentanyl infusion as the control group. Our primary outcome will be the total dose of intraoperative fentanyl bouluses.

Randomization will be achieved by using an online random number generator. Patient codes will be placed into sequentially numbered sealed opaque envelopes by a research assistant who is not involved in the study. A medical personnel not involved in patient management will be responsible for opening the envelope and give the instructions contained within each envelope to the anesthesiologist who is expert in doing the ESPB in patients included within the block group. this expert anaesthesiologist will not be involved in collecting data but another anaesthesia doctor will be responsible for patient management and collecting the intraoperative and postoperative data.

The study will be conducted in the pediatric cardiothoracic operation theatre in Abu El Reesh Pediatric Hospital -Cairo University on 28 pediatric patients aged 3 months-12 months, ASA III undergoing aortic coarcitectomy (with thoracotomy incision).

All patients will attend at the pre- anesthesia room with their parents 1 hour before the procedure after taking approval of research ethical comittee and informed consent.

Detailed history from the parents will be taken followed by a full and detailed clinical examination of the child then all investigations including CBC, coagulation profile, liver enzymes, kidney function tests, Chest x-ray ,echocardiography and blood grouping will be checked.

ECG, pulse oximetry and non-invasive blood pressure will be applied to all patients. All patients will be premedicated by intramuscular midazolam 2mg/Kg and atropine 0.2 mg/Kg 20 minutes before induction of anesthesia.

Anesthesia will be induced in all patients by sevoflurane 5% in 100% O2 followed by Placement of peripheral I.V cannula and IV administration of fentanyl (1-2µg/kg). Oral endotracheal intubation will be facilitated by IV atracurium 0.5 mg/kg and then capnogram will be connected to monitor End-tidal CO2 and muscle relaxation will be maintained by atracurium infusion in a dose of 0.5 mg/ kg/ hr.

All patients will be mechanically ventilated using pressure controlled mode with FiO2 50%, positive end expiratory pressure (PEEP) 5 cmH2O,I: E ratio of 1:2,peak inspiratory pressure (PIP) will be set to deliver a tidal volume of 6-8 ml/kg and respiratory rate will be 15 to 35 cycle / minute according to the age. our aim is to keep end tidal CO2 between 30-40 mmHg.

Sevoflurane will be used for maintenance of anaesthesia and its MAC will be determined by using bispectoral index (targeting 40-60) to standardize the depth of anaesthesia.

After insertion of a central venous catheter and an arterial cannula , nasopharyngeal temperature probe will be placed and the patient's position will be changed from supine to right lateral position.

02

Conditions studied

  • Aortic Coarctation
  • Erector Spinae Plane Block
  • Paediatric

Browse trials for

03

In context

Aortic Coarctation

49 studies on the registry are indexed under Aortic Coarctation; 16 are open to participants now.

This study's enrollment of 28 is below the median of 45 across 19 interventional studies indexed under Aortic Coarctation.

Browse Aortic Coarctation studies →

Lead sponsor

Cairo University is the lead sponsor of 4,941 studies on the registry; 1,458 are open to participants now.

Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Months to 12 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age: 3 months-12 months.
  2. A III .
  3. Patients undergoing aortic coarcitectomy operation undergone with Lateral thoracotomy incision.

Exclusion criteria

Exclusion Criteria:

  1. Patients whose parents or legal guardians refusing to participate.
  2. Preoperative mechanical ventilation.
  3. Preoperative inotropic drug infusion.
  4. Patients undergoing aortic coarctectomy operation undergone with midline sternotomy incision.
  5. Known or suspected coagulopathy.
  6. Any congenital anomalies of the sacrum/the vertebral column or any infection at the site of injection.
  7. Known or suspected allergy to any of the studied drugs.
  8. Elevated liver enzymesmore than the normal values.
  9. Renal function impairment (Creatinine value more than 1.2mg/dl or blood urea nitrogen more than 20mg/dl).
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
28 participants (actual)

Study arms

  • Other
    Control group

    This group will receive fentanyl infusion only

    Drug: Fentanyl

  • Active comparator
    ESPB group

    This group will receive fentanyl infusion plus Ultrasound guided ESPB

    Drug: Fentanyl · Procedure: Erector spinae plane block

Interventions

  • fentanyl infusion at a dose of (1 μg/kg/hour) after induction of anesthesia and to be continued all through the whole operation.rescue analgesia by a bolus of (Fentanyl 1mcg/kg) will be given to the patients in either group, if either systolic blood pressure or heart rate increased more than 20% of the baseline readings.

  • ProcedureErector spinae plane block

    ultrasound guided erector spinae plane block by injecting 0.4ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%). This will be performed at the same side of the planned thoracotomy under strict aseptic precautions.A high frequency 12 MHz linear ultrasound transducer will be placed in a longitudinal orientation 3 cm lateral to the T3 spinous process corresponding to the T2 transverse process. Three muscles; trapezius, rhomboids major, and erector spinae will be identified superior to the hyperechoic transverse process. Using in-plane approach a 25 G needle will be inserted in caudal-cephalic direction, until the tip is deep to erector spinae muscle. Correct needle tip location will be confirmed by injecting 3 mL of normal saline and visualizing the linear LA spread in the fascial plane between the erector spinae muscle and the transverse process..

06

What researchers measure

Primary outcomes

  1. The total dose of intraoperative fentanyl boluses.

    microgram/kg

    Time frame: From skin incision till 5 minutes after skin closure

Secondary outcomes

  1. Face, Leg, Activity, Cry, Consolability

    1. Face * 0: if patient has a relaxed face * 1: if patient has a worried look ,eyes partially closed, mouth pursed * 2: if patient has deep furrows in the forehead, with closed eyes, open mouth. 2. Legs * 0: if patient has usual tone and motion to limbs. * 1: if patient has increase tone, rigidity. * 2: if patient has hyper tonicity, legs pulled tight, exaggerated flexion/extension of limbs. 3. Activity * 0: if patient moves easily and freely. * 1: if patient shifts positions, guarding. * 2:if patient is in fixed position, side-to-side head movement. 4. Cry * 0: if patient has no cry/moan awake or asleep * 1: if patient has occasional moans, cries. * 2: if patient has frequent/continuous moans, cries, grunts. 5. Consolability * 0: if patient is calm and does not require consoling * 1: if patient responds to comfort by touch or talk in ½- 1 minute * 2: if patient requires constant comforting or unable to console.

    Time frame: 30 min, 60 min, 2 hours, 4hours, 8hours, 16hours and 24 hours postoperatively

  2. postoperative Morphine

    mg/kg

    Time frame: 30 minutes postoperative till 24 hours postoperative

07

Study locations

1 site
  • Kasr Al-Ainy Hospital
    Cairo, 11562, Egypt
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2020 to primary completion in Jul 2021, 17 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2019
First posted
Oct 16, 2019
StartActual
Feb 1, 2020
Primary completionActual
Jul 30, 2021
CompletionActual
Jul 30, 2021
Last update
Jul 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04128540
Lead sponsor
Cairo University
Responsible party
Mina Kamal Harees Abdo (Assistant Lecturer, Cairo University) — Principal investigator
First posted
Oct 16, 2019
Start date
Feb 1, 2020
Primary completion
Jul 30, 2021
Completion
Jul 30, 2021
Last update
Jul 8, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion